Dregeoside Ga1 is primarily investigated for its potential anti-inflammatory and immunomodulatory properties. It has shown activity in regulating cytokine production, particularly suppressing pro-inflammatory mediators such as TNF-α and IL-6, making it a candidate of interest in the development of therapeutics for chronic inflammatory conditions. Research also suggests it may influence metabolic pathways related to oxidative stress, offering possible applications in protecting against cellular damage. Due to its natural origin and bioactive profile, Dregeoside Ga1 is being explored as a lead compound in phyto-pharmaceuticals, especially in formulations targeting immune-related disorders and inflammatory diseases.